Citius Oncology, Inc. recorded its first product revenue of $3.9 million following the December 2025 commercial launch of LYMPHIR, an FDA-approved immunotherapy treatment for cutaneous T-cell lymphoma. The biopharmaceutical company successfully established nationwide distribution infrastructure and implemented an artificial intelligence-enabled commercial platform to support the drug's market entry.
Despite the significant milestone of achieving initial revenue, Citius Oncology reported a net loss of $5.5 million for the first quarter of 2026, reflecting ongoing operational costs associated with the launch phase and company infrastructure. The company maintained a cash position of $7.3 million as of December 31, 2025, which will be critical as it continues to scale commercialization efforts for LYMPHIR.
The successful launch represents a key inflection point for Citius Oncology as it transitions from a pre-commercial development stage to an operating biopharmaceutical company with marketed product revenue. The deployment of AI-enabled commercial tools underscores the company's approach to optimize market penetration and patient access in the competitive oncology therapeutics sector.